Abivax S.A. Launches IPO

Abivax S.A. Launches IPO (ABVX),Offers 18.68 Million Shares, Best Details

by

Abivax S.A. Launches IPO

(ABVX) Offers 18.68 Million Shares at $13.50 Per Share

On October 16, 2023, Abivax S.A. (ABVX), a clinical-stage biotechnology company based in France, made its initial public offering (IPO) on the Nasdaq Stock Exchange. The company’s goal is to develop therapeutics that will allow patients with chronic inflammatory diseases to modify their immune response by utilising the body’s natural regulatory mechanisms.

18.68 million American Depositary Shares (ADSs) at a price of $13.50 each are being offered by the corporation. An estimated $250 million in gross proceeds are anticipated from the IPO.

Abivax intends to use the money raised from the initial public offering (IPO) to support the ongoing research and development of obefazimod, its flagship medication candidate, which is presently being studied in Phase 3 clinical trials to treat individuals with moderately to highly active ulcerative colitis (UC).

An oral, first-in-class small molecule called obefazimod has been shown to increase the expression of miR-124, a crucial player in the control of the inflammatory response.

The development of Abivax’s additional pipeline candidates, which are undergoing Phase 2 clinical trials for the treatment of Crohn’s disease and systemic lupus erythematosus (SLE), will also be funded by the IPO proceeds.

Abivax S.A. (ABVX) IPO Details

  • Number of shares offered: 18.68 million ADSs
  • Price per share: $13.50
  • Total value of IPO: $250 million

Note: The IPO has not yet closed, so the final price and value may vary.

Analyst Opinion on the Abivax IPO

The majority of analysts are optimistic about the Abivax IPO. The company is developing a number of products, and the primary medication candidate is progressing well in clinical studies. The business is also aiming to capitalise on the sizable and expanding market for chronic inflammatory illnesses.

Analysts do point out that given the volatility of the biotech industry in recent months, investors would be wary of funding a startup. Furthermore, there is no assurance that the company’s principal medicine candidate will be authorised by the FDA as it is currently in Phase 3 clinical studies.

Conclusion

The Abivax IPO is a risky investment, but it also has the potential to be very rewarding. Investors should carefully consider their own risk tolerance and investment goals before investing in the IPO.

What is Abivax S.A.?

French clinical-stage biotechnology startup Abivax S.A. is creating medicines that use the body’s built-in regulatory systems to control the immune system in individuals suffering from long-term inflammatory conditions.

How much money is Abivax hoping to raise in its IPO?

Abivax is hoping to raise approximately $250 million in its IPO.

What are the risks of investing in the Abivax IPO?

A risky investment is making an IPO investment in Abivax. Phase 3 clinical studies are still ongoing for the company’s principal therapeutic candidate, as it is still in its early phases of development.
The company’s ability to successfully develop and market its products is not guaranteed. Furthermore, the biotech industry is erratic, and the stock price of the company could change a lot following the IPO.

How do I invest in the Abivax IPO?

Investors can use a broker who is a Nasdaq Stock Exchange member to participate in the Abivax IPO. To find out more about the IPO and how to participate, investors should get in touch with their broker.